Myostatin inhibitory peptide 3d

Myostatin inhibitory peptide 3d

• COA/MS/HPLC Report
• Handling and Storage of Synthetic Peptides
• Material Safety Data Sheets (MSDS)

Batch to batch variation of the purity

XRQNTRYSRIEWIKIQIISKLRL-NH2(X = 2-naphthoxyacetyl group)

23

95.8%

C₁₃₉H₂₂₅N₄₁O₃₃

2998.57

Synthetic

Powder

Myostatin, a negative regulator of skeletal muscle growth, is a promising target for treating muscle atrophic disorders. A novel peptide myostatin inhibitory peptide 3d displayed an IC50 value of 0.32 μM, which is 11 times more potent than peptide(WRQNTRYSRIEAIKIQILSKLRL-amide). The peptide 3d would have the potential to be a promising drug lead to develop better peptidomimetics.

Normally, this peptide will be delivered in lyophilized form and should be stored in a freezer at or below -20 °C. For more details, please refer to the manual: Handling and Storage of Synthetic Peptides

• Takayama K, Rentier C, Asari T, et al. Development of Potent Myostatin Inhibitory Peptides through Hydrophobic Residue-Directed Structural Modification. ACS Med Chem Lett. 2017;8(7):751-756

Trifluoroacetic acid (TFA) is a common counterion from the purification process using High-Performance Liquid Chromatography (HPLC). The presence of TFA can affect the peptide's net weight, appearance, and solubility.

Impact on Net Weight: The TFA salt contributes to the total mass of the product. In most cases, the peptide content constitutes >80% of the total weight, with TFA accounting for the remainder.

Solubility: TFA salts generally enhance the solubility of peptides in aqueous solutions.

In Biological Assays: For most standard in vitro assays, the residual TFA levels do not cause interference. However, for highly sensitive cellular or biochemical studies, please be aware of its presence.